MARKET WIREReuters • 3h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why CCEL Stock advanced +1.17% Today — RQD Quant Desk Flash
$5.19 +1.17% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.19
Cryo-Cell International Inc. (CCEL) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $41.8M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.19 (+0.02%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 0.1% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+2.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CCEL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (64/100 Composite)
🔍 WHY CCEL SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (27% of score)
SEC XBRL FY 2025 (10-K): 0.1% FCF Margin ($5.2M FCF) & 52% Gross Margin
▲ #2 Bullish Driver: Macro Regime Fit+15/20 pts (23% of score)
FRED Regime × Technicals: 90% of 52W Range • RSI-14 at 64.3 (BULLISH MOMENTUM)
▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$4.36+1.4% Next Q
56
Q2 (-2Q)Grade C$4.42+0.9% Next Q
59
Q3 (-1Q)Grade C$4.46+16.4% Next Q
61
CurrentGrade C$5.19+1.1% Hist 90D α
64
Trajectory: C (56) → C (64)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the CCEL Bull Thesis Could Fail
Even with a 64/100 (C) score, CCEL faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.31) or 200D SMA ($3.68) invalidates the momentum regime and cuts Target Base ($5.33) toward Bear Floor ($4.16).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CCEL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CCEL Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CCEL Stock advanced +1.17% Today — RQD Quant Desk Flash
Cryo-Cell International Inc. (CCEL) advanced +1.17% to $5.19, trading at 90% of its 52-week range ($2.72 – $5.45). Solid steady margins (18% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 90% of its 52-week range ($2.72 – $5.45) with RSI-14 at 64.3 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.19 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 52% gross margin and $5.2M annual free cash flow.
Live CCEL Headlines & Catalysts
MARKET WIRECNBC • 5h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 5h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 7h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 8h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 9h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 9h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 10h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (CCEL Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CCEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +51.75%▲ ASCENDING CHANNEL
2026-10-30O $5.10H $5.21L $5.00C $5.19VOL 12.0K
RES: $5.61SUP: $3.55SMA50: $4.31SMA200: $3.68
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CCEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
48.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CCEL today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CCEL. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CCEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CCEL)
Health Care Rank #147 of 1016
⚔️ PARK vs CCEL Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CCEL vs. PARK, NIVF, MGRX, VMD)
Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Cryo-Cell International Inc. (CCEL) ranks #147 by composite RQD confidence (64/100, grade C) and #770 by equity capitalization ($41.8M). Within this direct 5-issuer industry benchmark cohort, VMD leads on earnings valuation at 24.6x trailing P/E, while CCEL leads on capital efficiency and profitability with 18.2% ROIC and — gross margin. VMD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with CCEL at 64/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CCEL
ACTIVE
Cryo-Cell International Inc. | C | 64/100 | — | — | 18.2% | +1.17% | $41.8M | Benchmark Subject |
| PARK Park Dental Partners Inc. | D | 49/100 | — | — | — | -2.79% | $95.4M | /park-vs-ccel → |
| NIVF NewGenIvf Group Limited (Class A) | E | 22/100 | — | — | -32.8% | -5.00% | $11.3M | /nivf-vs-ccel → |
| MGRX Mangoceuticals Inc. | E | 34/100 | — | 54.9% | -35.0% | -1.47% | $5.7M | /mgrx-vs-ccel → |
| VMD Viemed Healthcare Inc. | C+ | 69/100 | 24.6x | 57.5% | 13.0% | -0.40% | $379.0M | /vmd-vs-ccel → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-11-30 • CIK 0000862692In its most recent audited fiscal period (FY2025, filed 2025-11-30), Cryo-Cell International Inc. (CCEL) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$2.4M, operating cash flow of $5.5M, and free cash flow of $5.2M (+45.5% YoY). On the balance sheet, CCEL closed FY2025 with $61.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-11-30 | $0 | -$2.4M | $5.5M | $5.2M | $61.7M | — |
| FY2024 (FY) | 2024-11-30 | $0 | $402.0K | $6.0M | $3.6M | $64.7M | — |
| FY2023 (FY) | 2023-11-30 | $0 | -$9.5M | $8.9M | $8.9M | — | — |
3. CCEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Cryo-Cell International Inc. (NYSE: CCEL) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $5.19 (+1.17% 1D, market cap $41.8M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, CCEL ranks #147 in composite RQD confidence.
How does CCEL compare to PARK and NIVF in the Health Care sector?
Within the Health Care sector (Misc Health and Biotechnology Services), CCEL carries a Roarable C (64/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 18.2%. By comparison, PARK (Park Dental Partners Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $95.4M) and NIVF (NewGenIvf Group Limited (Class A)) posts a E grade (22/100 RQD, P/E N/A, ROIC -32.8%, cap $11.3M). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CCEL?
Per CCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-11-30, CIK 0000862692), Cryo-Cell International Inc. generated $0 in revenue, -$2.4M in net income, and $5.2M in free cash flow against $61.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CCEL trading relative to its 50-day, 200-day, and 52-week technical levels?
CCEL last traded at $5.19 (+1.17% on volume of 8,072 shares), positioning the stock +20.42% above its 50-day simple moving average ($4.31) and +41.03% above its 200-day simple moving average ($3.68). Across its 52-week range of $2.72 to $5.45, CCEL sits at the 90.5% percentile with a 14-day RSI of 64.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.54 to $5.84).
CCEL Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CCEL stock moving today?
Why CCEL Stock advanced +1.17% Today — RQD Quant Desk Flash. Solid steady margins (18% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.